Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix

Smith, 2000, The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the united States. A 24-year population-based study, Gynecol. Oncol., 78, 97, 10.1006/gyno.2000.5826 Horowitz, 1988, Epidemiology of adenocarcinoma of the cervix, Gynecol. Oncol., 31, 25, 10.1016/0090-8258(88)90265-X Vizcaino, 1998, International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas, Int. J. Cancer, 75, 536, 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U Raab, 2000, Can glandular lesions be diagnosed in pap smear cytology?, Diagn. Cytopathol., 23, 127, 10.1002/1097-0339(200008)23:2<127::AID-DC13>3.0.CO;2-I Krane, 2001, Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases, Cancer, 93, 8, 10.1002/1097-0142(20010225)93:1<8::AID-CNCR9001>3.0.CO;2-K Ruba, 2004, Adenocarcinoma in situ of he uterine cervix. Screening and diagnostic errors in Papanicolau smears, Cancer Cytopath., 102, 280, 10.1002/cncr.20600 Walboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol., 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Zielinski, 2003, The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix, J. Pathol., 201, 535, 10.1002/path.1480 Derchain, 2004, Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears, Gynecol. Oncol., 95, 618, 10.1016/j.ygyno.2004.08.033 Andersson, 2001, The role of human papillomavirus in cervical adenocarcinomna carcinogenesis, Eur. J. Cancer, 37, 246, 10.1016/S0959-8049(00)00376-2 Cohn, 2005, Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins, Gynecol. Oncol., 98, 158, 10.1016/j.ygyno.2005.04.013 Shipman, 2001, Adenocarcinoma in situ and early invasive adenocarcinoma of the uterine cervix, Curr. Opin. Oncol., 13, 394, 10.1097/00001622-200109000-00014 Krivak, 2001, Cervical adenocarcinoma in situ: a systematic review of therapeutic options and predictors of persistent or recurrent disease, Obstet. Gynecol. Surv., 56, 567, 10.1097/00006254-200109000-00023 ACOG Practice Bulletin, 2005, Clinical management guidelines for obstetrician-gynaecologist. Management of abnormal cervical cytology and histology, Obstet. Gynecol., 106, 645 Bryson, 2004, Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS?, Gynecol. Oncol., 93, 465, 10.1016/j.ygyno.2004.01.028 Costa, 2003, Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization, Gynecol. Oncol., 90, 358, 10.1016/S0090-8258(03)00268-3 Cricca, 2006, HPV DNA patterns and disease implications in the follow-up of patients treated for HPV16 high-grade carcinoma in situ, J. Med. Virol., 78, 494, 10.1002/jmv.20567 Clement, 2000, 109 Zaino, 2002, Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix, Int. J. Gynecol. Pathol., 21, 314, 10.1097/00004347-200210000-00002 Costa, 2002, Disease persistence in patients with cervical intraepithelial neoplasia undergoing electrosurgical conization, Gynecol. Oncol., 85, 119, 10.1006/gyno.2001.6579 Sherman, 2005, Mortality trends for cervical squamous and adenocarcinoma in the United States, Cancer, 103, 1258, 10.1002/cncr.20877 Stockton, 1997, Changing incidence of invasive adenocarcinoma of the uterine cervix in East Anglia, J. Med. Screen, 4, 40, 10.1177/096914139700400112 Negri, 2003, p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and ist precursors, Am. J. Surg. Pathol., 27, 187, 10.1097/00000478-200302000-00006 Soutter, 2001, Is conservative treatment for adenocarcinoma in situ of the cervix safe?, BJOG, 108, 1184, 10.1016/S0306-5456(01)00277-7 Widrich, 1996, Adenocarcinoma in situ of the uterine cervix: management and outcome, Gynecol. Oncol., 61, 304, 10.1006/gyno.1996.0147 Muntz, 1996, Can cervical adenocarcinoma in situ be safely managed by conizations alone, Gynecol. Oncol., 61, 301, 10.1006/gyno.1996.0146 Ostor, 2000, Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases, Gynecol. Oncol., 79, 207, 10.1006/gyno.2000.5957 Akiba, 2005, Is laser conization adequate for therapeutic excision f adenocarcinoma in situ of the uterine cervix?, J. Obstet. Gynaecol. Res., 31, 252, 10.1111/j.1447-0756.2005.00279.x Kennedy, 2002, Further study of the management of cervical adenocarcinoma in situ, Gynecol. Oncol., 86, 361, 10.1006/gyno.2002.6771 Krivak, 2001, Cervical adenocarcinoma in situ: a systematic review of therapeutic options and predictors of persistent or recurrent disease, Obstet. Gynecol. Survey, 56, 179, 10.1097/00006254-200109000-00023 Azodi, 1999, Adenocarcinoma in situ of the cervix: management options, Gynecol. Oncol., 73, 348, 10.1006/gyno.1999.5395 Andersen, 2002, Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment, Gynecol. Oncol., 86, 365, 10.1006/gyno.2002.6758 Levenback, 1996, Adenocarcinoma in situ of the cervix: significance of cone biopsy margins, Obstet. Gynecol., 88, 82, 10.1016/0029-7844(96)00083-X Goldstein, 1998, The status and distance of cone biopsy margins as a predictor of excision adequacy for endocervical adenocarcinoma in situ, Am. J. Clin. Pathol., 109, 727, 10.1093/ajcp/109.6.727 Bertrand, 1987, The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment, Am. J. Obstet. Gyecol., 157, 21, 10.1016/S0002-9378(87)80338-1 McHale, 2001, Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix, Obstet. Gynecol., 98, 726, 10.1016/S0029-7844(01)01544-7 Im, 1995, Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease, Gynecol. Oncol., 59, 179, 10.1006/gyno.1995.0003 Plaxe, 1999, Estimation of the duration of the preliminary phase of cervical adenocarcinoma suggests that there is ample opportunity for screening, Gynecol. Oncol., 75, 55, 10.1006/gyno.1999.5524 Andersen, 1989, Adenocarcinoma in situ of the uterine cervix: a clinico-pathologic study of 36 cases, Gynecol. Oncol., 35, 1, 10.1016/0090-8258(89)90001-2 Shin, 2000, Conservative management of adenocarcinoma in situ of the cervix, Gynecol. Oncol., 79, 6, 10.1006/gyno.2000.5962 Saqi, 2006, High-risk human papillomavirus DNA testing: a marker for atypical glandular cells, Diagn. Cytopathol., 34, 235, 10.1002/dc.20369 Syrjänen, 2004, Improved detection of adenocarcinoma in situ (AIS) by screening. A key to reducing the incidence of cervical adenocarcinoma? Editorial, Acta Cytol., 48, 591, 10.1159/000326427 Wang, 2006, Pathological characteristics of cervical adenocarcinoma in a multi-center US-based study, Gynecol. Oncol., 103, 541, 10.1016/j.ygyno.2006.03.049